Drug Industry – Page 17

Lilly’s Future Brightens with Increased Visibility on Mounjaro and Zepbound Production Capacity

1 year ago talkbio0Tagged Capacity, Drug Industry, drug manufacturing, Eli Lilly, financial outlook, Mounjaro, production, Zepbound

Lilly, Mounjaro, Zepbound, production capacity, financial outlook, pharmaceutical industry, drug manufacturing.

AbbVie’s Skyrizi and Rinvoq Drive Growth, Counteracting Humira Decline

1 year ago talkbio0Tagged AbbVie, Drug Industry, drug sales, full-year outlook, Immunology, revenue growth, Rinvoq, Skyrizi

AbbVie, Skyrizi, Rinvoq, Humira, full-year outlook, pharmaceutical industry, revenue growth, drug sales, immunology drugs

UCB’s Strategic Shift: Bristol Myers ADC Partner’s CEO Takes the Helm

1 year ago talkbio0Tagged Administration occupational activities, CEO, Changing, Drug Industry, Myers, Partner in relationship, strategic shift, therapeutic autologous dendritic cells, UCB

UCB, management changes, CEO, Bristol Myers, ADC partner, strategic shift, pharmaceutical industry.

Novartis to Revise CRO Partnerships Amidst US Senate Bill Scrutiny

1 year ago talkbio0Tagged Chinese Language, CRO, Drug Industry, Novartis, Partnership, regulatory, Relationships, Revisions, Senate

Novartis, CRO relationships, US Senate bill, Chinese companies, pharmaceutical industry, regulatory changes, partnership revisions

AstraZeneca CEO Pascal Soriot’s Pay Rise Signals Succession Planning

1 year ago talkbio0Tagged AstraZeneca, CEO, Drug Industry, executive compensation, Pascal Soriot, Succession planning

AstraZeneca, Pascal Soriot, CEO, pay rise, succession planning, pharmaceutical industry, executive compensation.

Strategic Acquisition, Partnership, and Development of Innovative Assets in Biopharma

1 year ago talkbio0Tagged Acquisition (action), Biopharma, development aspects, Drug Development, Drug Industry, innovative assets, Market, Partnership, Portfolio diversification, Risk Management, strategic decision-making, trends qualifier

Biopharma, Innovative Assets, Acquisition, Partnership, Development, Strategic Decision-Making, Pharmaceutical Industry, Drug Development, Market Trends, Risk Management, Portfolio Diversification

Day One Outshines Novartis: FDA Approves Ojemda for Wider Pediatric Brain Tumor Treatment

1 year ago talkbio0Tagged Brain Neoplasms, Cancer Therapeutic Procedure, Clinical Trials, Drug Industry, Novartis, Ojemda, Pediatric brand name, United States Food and Drug Administration

Day One, Novartis, FDA, Ojemda, pediatric brain tumor, cancer treatment, clinical trials, pharmaceutical industry.

Novartis Boosts 2024 Sales Forecast, Gears Up for Major Cancer Drug Expansions

1 year ago talkbio0Tagged 2024, cancer drugs, drug expansions, Drug Industry, Health care facility, Neoplasms, Novartis, Sales - occupational activity

Novartis, 2024 sales outlook, cancer drugs, drug expansions, pharmaceutical industry, healthcare, oncology.

Roche’s Strategic Shift Affects 20% of New Molecules, as Cancer Candidates are Reassessed

1 year ago talkbio0Tagged cancer candidates, Drug Development, Drug Industry, Molecule, oncology research, Roche (company), strategic shift

Roche, pipeline, rethink, new molecules, cancer candidates, discard pile, strategic shift, pharmaceutical industry, drug development, oncology research

Eli Lilly Expands Manufacturing Capacity with Nexus Plant Acquisition Amid Ongoing Mounjaro and Zepbound Supply Challenges

1 year ago talkbio0Tagged Acquisition (action), Capacity, Drug Industry, Drug shortages, Eli, Eli Lilly, Manufacture, Mounjaro, Nexus manufacturing, Plants, Wisconsin, Zepbound

Eli Lilly, Nexus manufacturing plant, Wisconsin, Mounjaro, Zepbound, drug shortages, manufacturing capacity, pharmaceutical industry, acquisition